Last reviewed · How we verify
Aprepitant+palonosetron+dexamethasone
This combination blocks chemotherapy-induced nausea and vomiting (CINV) through three complementary pathways: NK1 receptor antagonism, 5-HT3 receptor antagonism, and glucocorticoid anti-inflammatory effects.
This combination blocks chemotherapy-induced nausea and vomiting (CINV) through three complementary pathways: NK1 receptor antagonism, 5-HT3 receptor antagonism, and glucocorticoid anti-inflammatory effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | Aprepitant+palonosetron+dexamethasone |
|---|---|
| Also known as | PDA |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Drug class | Antiemetic combination (NK1 antagonist + 5-HT3 antagonist + corticosteroid) |
| Target | NK1 receptor, 5-HT3 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center. Palonosetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple mechanisms including glucocorticoid receptor activation. Together, these agents provide comprehensive CINV prophylaxis across acute, delayed, and breakthrough phases.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Fatigue
- Constipation
- Diarrhea
- Hiccups
- Dizziness
Key clinical trials
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: